Skip to main content
. 2017 Jul 22;8(41):69906–69915. doi: 10.18632/oncotarget.19436

Figure 7.

Figure 7

(A, B) The growth of U937 cells (A) and HL-60 cells (B) treated with 5 μM AZA and/or 1 μM teriflunomide (TFN) for 42 days. *p < 0.01 in comparison with mock or TFN-treated cells, #p < 0.01 in comparison with AZA-treated cells. (C, D) The AZA sensitivity of U-937 cells (C) and HL-60 cells (D) treated with 5 μM AZA and/or 1 μM TFN for 42 days.